If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Corrigendum to “Does Natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion” [Multiple Scler. Relat. Disord. 2 (4) (2013) 385–387]
The authors wish to include the following Fig. 1 and legend which were inadvertently omitted from the original manuscript despite being mentioned in the text of paragraph 1.3 (page 386).
Fig. 1T2W axial (a–c) images and a FLAIR coronal (d) MR image demonstrate high T2 signal in the medial aspect of the right temporal lobe, insular cortex and anterior perforated substance highly suggestive of herpes encephalitis.
This report presents the 4th documented case worldwide of herpes simplex encephalitis in multiple sclerosis (MS) patients treated with natalizumab and the first case in the UK. Natalizumab is licensed for relapsing remitting multiple sclerosis in patients with high disease activity despite treatment with interferon-beta and patients with rapidly evolving severe, multiple sclerosis. Natalizumab is a monoclonal antibody targeted against alpha-4 integrin. Its proposed mechanism is attenuation of the migration of immune cells into the central nervous system.
00086-2&id=gr1.jpg){kind=link}